Xin Lang Cai Jing·2025-11-14 02:05Core Viewpoint - Rongchang Biopharmaceuticals has experienced significant stock price fluctuations and is focusing on innovative biopharmaceuticals, particularly in the field of therapeutic antibodies [1][2][3]. Financial Performance - As of September 30, 2025, Rongchang Biopharmaceuticals reported a revenue of 1.72 billion yuan, representing a year-on-year growth of 42.27% [3]. - The company recorded a net profit attributable to shareholders of -551 million yuan, which is a 48.60% increase compared to the previous period [3]. Stock Market Activity - On November 14, 2025, the stock price of Rongchang Biopharmaceuticals fell by 2.04%, trading at 87.18 yuan per share with a market capitalization of 49.135 billion yuan [1]. - The stock has increased by 189.54% year-to-date, with a recent 5-day increase of 0.28% and a 20-day decline of 10.47% [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 18.33% to 15,300, while the average circulating shares per person decreased by 15.54% to 10,639 shares [3][4]. - Major shareholders include Hong Kong Central Clearing Limited and Wanjiayouxuan, with notable changes in their holdings [4].